160
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

The molecular evaluation of thioredoxin (TXN1 & TXN2), thioredoxin reductase 1 (TXNRd1), and oxidative stress markers in a binary rat model of hypo- and hyperthyroidism after treatment with gallic acid

, , , &
Pages 1108-1115 | Received 13 May 2022, Accepted 25 Sep 2022, Published online: 31 Oct 2022

References

  • Asci, H., et al., 2017. The impact of gallic acid on the methotrexate-induced kidney damage in rats. Journal of Food and Drug Analysis, 25 (4), 890–897.
  • Benzie, I.F., and Strain, J.J., 1996. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Analytical Biochemistry, 239 (1), 70–76.
  • Bhimte, B., et al., 2012. Oxidative stress status in hypothyroid patients. Biomed Research, 23, 286–288.
  • Choubey, S., et al., 2015. Medicinal importance of gallic acid and its ester derivatives: a patent review. Pharmaceutical Patent Analyst, 4 (4), 305–315.
  • Chu, Y.-F., et al., 2002. Antioxidant and antiproliferative activities of common vegetables. Journal of Agricultural and Food Chemistry, 50 (23), 6910–6916.
  • Cooper, D.S., et al., 1983. Propylthiouracil (PTU) pharmacology in the rat, II. Effects of PTU on thyroid function. Endocrinology, 113 (3), 921–928.
  • Damdimopoulos, A.E., et al., 2002. Human mitochondrial thioredoxin: involvement in mitochondrial membrane potential and cell death. The Journal of Biological Chemistry, 277 (36), 33249–33257.
  • Das, K., and Chainy, G., 2001. Modulation of rat liver mitochondrial antioxidant defence system by thyroid hormone. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1537 (1), 1–13.
  • Fabbrini, E., et al., 2014. Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects. Diabetes, 63 (3), 976–981.
  • Gasdaska, P.Y., et al., 1995. Cloning and sequencing of a human thioredoxin reductase. FEBS Letters, 373 (1), 5–9.
  • Ghareeb, H., and Metanis, N., 2020. The thioredoxin system: a promising target for cancer drug development. Chemistry (Weinheim an der Bergstrasse, Germany), 26 (45), 10175–10184.
  • Guerrero, A., et al., 1999. Effect of thyroid status on lipid composition and peroxidation in the mouse liver. Free Radical Biology & Medicine, 26 (1–2), 73–80.
  • Hu, M., and Dillard, C., 1994. Plasma SH and GSH measurement. Methods in Enzymology, 233, 385–387.
  • Kaur, M., et al., 2009. Gallic acid, an active constituent of grape seed extract, exhibits anti-proliferative, pro-apoptotic and anti-tumorigenic effects against prostate carcinoma xenograft growth in nude mice. Pharmaceutical Research, 26 (9), 2133–2140.
  • Kihara, M., et al., 2005. Expression of thioredoxin in patients with Graves’ disease. International Journal of Molecular Medicine, 15, 795–799.
  • Kim, S.-H., et al., 2006. Gallic acid inhibits histamine release and pro-inflammatory cytokine production in mast cells. Toxicological Sciences : An Official Journal of the Society of Toxicology, 91 (1), 123–131.
  • Klein, I., and Danzi, S., 2007. Thyroid disease and the heart. Circulation, 116 (15), 1725–1735.
  • Kochman, J., et al., 2021. The influence of oxidative stress on thyroid diseases. Antioxidants, 10 (9), 1442.
  • Ladenson, P.W., et al., 1986. Modulation of myocardial L-triiodothyronine receptors in normal, hypothyroid, and hyperthyroid rats. Metabolism: Clinical and Experimental, 35 (1), 5–12.
  • Lee, D., et al., 2019. Induction of oxidative stress through inhibition of thioredoxin reductase 1 is an effective therapeutic approach for hepatocellular carcinoma. Hepatology (Baltimore, Md.), 69 (4), 1768–1786.
  • May, J.M., Morrow, J.D., and Burk, R.F., 2002. Thioredoxin reductase reduces lipid hydroperoxides and spares α-tocopherol. Biochemical and Biophysical Research Communications, 292 (1), 45–49.
  • Ogunsanwo, O.R., et al., 2017. Biochemical and electrocardiographic studies on the beneficial effects of gallic acid in cyclophosphamide-induced cardiorenal dysfunction. Journal of Complementary and Integrative Medicine, 14 (3).
  • Okaichi, Y., et al., 2005. Arachidonic acid improves aged rats’ spatial cognition. Physiology & Behavior, 84 (4), 617–623.
  • Padma, V.V., et al., 2013. Oral treatment with gallic acid and quercetin alleviates lindane-induced cardiotoxicity in rats. Canadian Journal of Physiology and Pharmacology, 91 (2), 134–140.
  • Petrulea, M., et al., 2012. Oxidative stress and antioxidant status in hypo-and hyperthyroidism. Antioxidant Enzyme, 3 (8), 197–236.
  • Priscilla, D.H., and Prince, P.S.M., 2009. Cardioprotective effect of gallic acid on cardiac troponin-T, cardiac marker enzymes, lipid peroxidation products and antioxidants in experimentally induced myocardial infarction in Wistar rats. Chemico-Biological Interactions, 179 (2–3), 118–124.
  • Sato, A., et al., 1995. Hyperuricemia in patients with hyperthyroidism due to Graves’ disease. Metabolism: Clinical and Experimental, 44 (2), 207–211.
  • Taylor, P.N., et al., 2018. Global epidemiology of hyperthyroidism and hypothyroidism. Nature Reviews. Endocrinology, 14 (5), 301–316.
  • Türkoğlu, E., et al., 2019. Inhibitory effects of some flavonoids on thioredoxin reductase purified from chicken liver. Brazilian Journal of Poultry Science, 21 (2), 1–7.
  • Wiersinga, W., 1995. Subclinical hypothyroidism and hyperthyroidism. I. Prevalence and clinical relevance. The Netherlands Journal of Medicine, 46 (4), 197–204.
  • Wollman, E., et al., 1988. Cloning and expression of a cDNA for human thioredoxin. The Journal of Biological Chemistry, 263 (30), 15506–15512.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.